Business
Add as a preferred source on GoogleThe result rose from $0.67 a year earlier; analysts’ pre-release consensus implied a 4.5% year-over-year earnings decline.
Viatris reported adjusted earnings per share of $0.71 for the third quarter, exceeding analysts’ $0.64 consensus and giving investors a result above the pre-release benchmark.
The figure rose from $0.67 a year earlier. Viatris released its third-quarter results on Nov. 5.
Third-quarter pharmaceutical sales topped analysts’ average, while Bayer reduced its projected cash outflow and lowered its year-end net debt forecast.
Consensus estimates put quarterly earnings at $0.46 per share, with the release scheduled before U.S. markets open Tuesday, Nov. 3.
Net sales rose 3% to $3.2755 billion, but organic constant-currency growth was 0.8% as lower volume offset higher pricing.
